Conference Coverage Most recent phase 3 trials of patients with newly diagnosed glioblastoma have shown no significant improvement in overall survival with the experimental treatment.
Deaths among patients with primary malignant brain tumors are on the rise in the United States, data suggest.
Patients with glioma do not have an increased risk of SARS-CoV-2 infection or worse outcomes from COVID-19, a single-center study suggests.
Children and adolescents with medulloblastoma frequently suffer from neuroophthalmological sequelae, a single-center study suggests.
Researchers say they have identified a molecular signature that can be used to predict outcomes of regorafenib treatment in patients with recurrent glioblastoma.
VAL-083 in combination with radiotherapy is safe and active in patients with newly diagnosed MGMT-unmethylated glioblastoma, a phase 2 trial suggests.
Among glioblastoma patients, women may derive more benefit from immunotherapy than men, research suggests.
Patterns of relapse are similar in patients with standard-risk and high-risk medulloblastoma, a review suggests.
Nearly a third of patients with high-grade glioma who were prescribed opioids after surgery continued to take them beyond the perioperative setting.
Adding interferon-α to adjuvant temozolomide can prolong overall survival in patients with high-grade glioma, a phase 3 trial suggests.
Recurrence of esthesioneuroblastoma with non-contiguous intracranial metastasis is possible 19 years after remission, a review suggests.
There are several steps health care providers can take to help patients with CNS cancers navigate the disability application process.
Tovorafenib produced responses in young patients with progressive or recurrent BRAF-altered low-grade glioma in a phase 2 trial.
The sequence of treatment with rolapitant and ondansetron does not appear to impact chemoradiation-induced nausea and vomiting.
About 1 in 10 patients with high-grade glioma had a palliative care consultation before the end-of-life phase, researchers found.
Load More
